William B. Harrison, Jr.
From Wikipedia, the free encyclopedia
William B. Harrison, Jr., born August 12, 1943 in Rocky Mount, North Carolina, is the former CEO and Chairman of JPMorgan Chase. He attended the University of North Carolina at Chapel Hill, where he was admitted to the Zeta Psi fraternity. Having risen through the ranks of Chemical Bank before succeeding Walter V. Shipley as the leader of the Chase Manhattan Corporation, he and Douglas A. Warner III, then CEO of J.P. Morgan & Co., were the principal architects of the US$30.9 billion Chase and J.P. Morgan & Co. merger of 2000.[1] Harrison has been a director of the Firm or a predecessor institution since 1991. Mr. Harrison is also a director of Merck & Co., Inc.
Jamie Dimon, former Bank One CEO, will replace Harrison as Chairman on January 1st, 2007 [2] following Harrison's decision to step down from his Chairman position of JPMorgan on December 31, 2006.
[edit] Resume
- A.B. degree in economics from the University of North Carolina
- Graduate of the Harvard Business School’s International Senior Management Programme in Switzerland
Director since 1991 of JPMorgan Chase or a predecessor institution:
- Vice Chairman of the Board of The Chase Manhattan Corporation, 1991 through June 1999
- President and Chief Executive Officer of The Chase Manhattan Corporation, June through Dec. 1999
- Chairman and Chief Executive Officer of The Chase Manhattan Corporation, Jan. 2000 through its merger with J.P. Morgan & Co. Incorporated, in Dec. 2000
- President and Chief Executive Officer of JPMorgan Chase, Dec. 2000 through Nov. 2001
- Chairman and Chief Executive Officer of JPMorgan Chase, Nov. 2001 through Dec. 2005
- Became Chairman of JPMorgan Chase on December 31, 2005
[edit] Footnotes and references
- ^ McGeehan, Patrick; Hansell, Saul. (Sept. 14, 2000). New York Times. Banking's Big Deal: The Deal; Chase Hopes Deal for Morgan will bring it Prestige. Late Edition - Final, Section C, Page 1, Column 2.
- ^ JP Morgan Press Release, 12 December 2006
- ^ Members of the Board Biography: William B. Harrison, Jr.
| Merck & Co., Inc. |
|---|
|
Corporate Directors: Lawrence Bossidy | William Bowen | Richard Clark | Johnnetta Cole | William Harrison | William Kelley | Rochelle Lazarus | Thomas Shenk | Anne Tatlock | Samuel Thier | Wendell Weeks | Peter Wendell |
|
Key products: Indinavir | Aprepitant | Alendronate | Rizatriptan | Finasteride | Montelukast | Rofecoxib | Ezetimibe/simvastatin | Ezetimibe | Simvastatin | The Merck Index | The Merck Manual |
|
Annual Revenue: $22.9 billion USD ( |
 |
This article about an American businessperson is a stub. You can help Wikipedia by expanding it. |
